Safety pharmacology is a relatively new and rapidly growing discipline. The primary regulatory documents governing safety pharmacology is the ICH Harmonised Tripartite Guidelines S7A and S7B. The stated goal of these documents is "To help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals". These ICH documents serve as guidelines and provide recommendations regarding the approach to evaluate therapeutics with respect to core organ systems (cardiovascular, respiratory and central nervous systems), supplemental organ systems (e.g., GI and renal) and follow-up studies to describe effects and mechanisms of action. The objective of this course is to provide an overview of safety pharmacology, current regulations and how they relate to drug development. This course is a broad overview of the common test systems and is therefore a good prerequisite to the more advanced continuing education courses offered. The course will include presentations from principal scientists with emphasis on the regulatory environment and the current state-of-the-art methodologies specific to each of the core battery and supplemental organ systems assays. These didactic presentations will be followed by a presentation and group discussions on integrated risk assessment in safety pharmacology.
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Pharmacokinetic principles and technologies characterize and quantify exposure to parent drug and metabolites in preclinical studies (including Safety Pharmacology) and in clinical trials. Safety pharmacology studies are best interpreted, and potential drug effects on organ system functions mitigated in terms of assessment of human risk thru comparative pharmacokinetics. However, while associations of drug-induced changes in organ functions and exposures in safety pharmacology studies are best accomplished when these measurements are collected coincidently in the same animals, the blood collection procedures and necessary blood volumes have necessitated used of separate satellite groups or reliance on pharmacokinetic/toxicokinetic assessments in separate studies, especially when using small animals. Recent advances in microsampling and microanalysis technologies now permit safety pharmacology and pharmacokinetic endpoints in the same study animals without compromise, affording opportunities to improve study data quality, reduce animal study numbers (Refinement and Reduction improvements), and to identify biomarkers with which to mitigate risk in human clinical trials. This course will deliver general principles and technologies of modern pharmacokinetic sampling, data acquisition, manipulation and interpretation, and current status of microsampling/dried blood spot technologies for safety pharmacologists. PhD, Covance Laboratories, Inc., Greenfield, IN and Pierre Morissette, PhD, Merck & Co., Inc., West Point, PA This course examines the practice and philosophy of conducting studies designed to illuminate safety risk earlier in the drug development process (frontloading). Frontloading can be defined as those safety assessments conducted during lead optimization of compounds before selection as a candidate drug for development and before regulatory studies are performed. The goal of early safety assessment or frontloading is to provide quality safety data that can drive development decisions much earlier in the flow scheme. Such studies also save resources by reducing late stage attrition. The course will examine what methods and processes have been successfully applied at reducing attrition and to provide "no surprises" approach to later stage GLP safety studies. Various practices and philosophy will be discussed by the speakers with adequate time for class discussion. -The pathways responsible for development of potential abuse will be introduced to gain more understanding at the molecular level. -The different aspects of drug abuse (physical dependence, conditioning and rewarding, reinforcing properties) and the various methods to investigate each of these dimensions will be discussed in detail. The impact of the GLP requirements as stated within the guidelines will also be assessed. -For new molecular entities (NMEs) with novel mechanisms of action: what is a complete and robust nonclinical package on drug abuse potential for these compounds? What are possible variables in the test designs or within the package itself that might contribute to the identification of drug abuse potential if modified on a scientific basis? Lastly the translational approach will be taken into account. What"s the predictability of a preclinical package for drug abuse potential for NMEs in development and how will the next steps towards clinical evaluation be set? The recently issued U.S. FDA Guidance for Industry draft document entitled "Assessment of Abuse Potential of Drugs" discusses potentially useful animal behavioral pharmacology study designs. Within this section of the document, the use of several species is indicated (usually rodents and primates). This session intends to address the potential issues surrounding appropriate species selection for abuse liability testing. The session will include a brief review of the models in each species with a focus on the strength and weaknesses of each approach. This will be followed by an open discussion of when a rodent or a nonhuman primate model would provide the most valid approach for successful evaluation of the abuse potential of novel medications in development. This session will discuss challenges for both the Safety Pharmacology and Biodefense communities in determining the predictive value of preclinical models to observed effects or adverse events associated with drugs that have progressed into clinical trials. Both communities are interested in technologies enabling better identification of lead compounds to reduce attrition earlier in the pipeline.
All medical countermeasures developed for biodefense indications (e.g., anthrax, Ebola, smallpox) must go through the U.S. FDA regulatory process. An additional challenge is that for biodefense indications, it is anticipated that licensure of medical countermeasures will be conducted under the U.S. FDA Animal Rule (21 CFR Parts 314 and 601), due to ethical constraints surrounding efficacy testing.
The Biodefense community is especially concerned with investing in technologies (whether for whole animal models or for in vitro studies such as the Langendorff prep for cardiac safety studies) likely to yield near-term benefits and seeks to learn from the experience of the Safety Pharmacology Society in development of preclinical models. Track Leader: JoAnne Saye, PhD, AstraZeneca Pharmaceuticals, Wilmington, DE Co-Chairs: Alan Bass, PhD, Merck Research Laboratories, Kenilworth, NJ and Peter Hoffmann, Ph.D., Novartis Pharma AG, Basel, Switzerland Development of drugs for the treatment of type 2 diabetes has become more complex as a result of the experience with registered treatments that have demonstrated significant cardiovascular hemodynamic adverse events (e.g., congestive heart failure associated with PPAR agonists), as well as those events that have presented in various other forms (e.g., potential for cardiac arrhythmias and myocardial infarction associated, respectively, with certain sulfonylureas and PPAR agonists) and were only evident through a meta analysis of a body of clinical data.
In some cases, these concerns are not necessarily linked to known mechanisms of cardiovascular toxicity, but illustrate the unique challenges with which safety pharmacologists are faced in the current strategic discovery and development environment. In other words, the safety pharmacologist is being asked to identify potential cardiovascular toxicities of novel new agents at a very early stage of research, when little is know about the novel efficacy target, including those toxicities that may emerge after months, years or decades of exposure. It is clear from deliberations of this critical topic and related topics at recent conferences and workshops that the state of science is not yet complete to assume all of these challenges.
The intent of this session is to provide a broad background to the issues, state of science and identify those gaps that deserve the focus of the Safety Pharmacology community. To that end, the faculty will include individuals from Safety Pharmacology and toxicology/pathology, who will engage the audience in a debate of this important topic. It is a decade since the birth of the Safety Pharmacology Society, an event largely triggered by the emergence of the ICH S7 guidance. The "QT issue" is also largely credited as the subject which gave the emerging society its focus and foundation. There is also renewed scrutiny on the ICH S7b and E14 documents.
Now 10 years later, this session will examine what has changed and have we made a difference by examining the question through the eyes of speakers who were very much involved in the issue at the time. 
